24/7 Market News Snapshot 24 Jun 2024 – Revelation Biosciences, Inc. Common Stock (NASDAQ: REVB)

June 24, 2024 8:10

Press Release

DENVER, Colo., 24 June, 2024 (247marketnews.com) – (NASDAQ:REVB) are discussed in this article.
Revelation Biosciences, Inc. (NASDAQ:REVB) has been making headlines with its Common Stock (REVB) as it experiences a remarkable surge in pre-market trading, showcasing a 40.43% increase to reach $2.867. This uptrend follows a previous session close at $2.11 and a notable trading volume of 1.3 million shares, attracting keen interest from investors eyeing the potential growth prospects of this stock.

Beyond its impressive stock performance, Revelation Biosciences has achieved a significant breakthrough in its Phase 1 clinical study for Gemini, a proprietary formulation designed to revolutionize disease prevention and treatment. Known as RVL-HV02, the study focused on assessing Gemini’s safety and tolerability among healthy volunteers, demonstrating encouraging outcomes that pave the way for expanded research initiatives across diverse medical conditions.

The clinical findings revealed that Gemini exhibited excellent safety profiles and tolerability at pharmacologically active doses, pinpointing the maximum tolerated dose in a cohort of healthy adults aged 18 to 55. Moreover, the study highlighted substantial, dose-dependent enhancements in essential circulatory biomarkers, showcasing Gemini’s potent immunostimulatory effects that could reshape innate immune responses, promote inflammation resolution, and enhance healing processes.

These promising results align closely with preclinical data showcasing Gemini’s efficacy in models of acute kidney injury and kidney-related conditions, positioning the formulation as a promising candidate for mitigating issues like post-surgical infections and acute kidney injury following cardiac procedures.

James Rolke, CEO of Revelation Biosciences, lauded the study outcomes, emphasizing the consistency between the biomarker data from human trials and preclinical investigations. Rolke expressed confidence in Gemini’s potential as a single-dose preconditioning therapy for targeted medical indications, underscoring the Company’s plans to swiftly progress into a Phase 1b study involving patients later this year.

Powered by phosphorylated hexaacyl disaccharide (PHAD®) technology, Gemini leverages toll-like receptor 4 (TLR4) agonism to harness trained immunity for combating various diseases. The formulation’s unique approach offers a new frontier in disease prevention and treatment, particularly in the realms of acute kidney injury and post-surgical infections, with broader applications envisioned for chronic kidney diseases.

Revelation Biosciences remains at the forefront of pioneering research aimed at leveraging trained immunity for medical advancements. For additional insights into Revelation Biosciences and its transformative initiatives, please visit www.RevBiosciences.com.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.